Version May 2024
| Antilymphocyte globulins (T cell depleting antibodies) |
| Activation of latent viruses, particularly herpes viruses fever, cytokine release |
| Glucocorticoids |
| Bacteria, Pneumocystis pneumonia (PCP), molds, activation of hepatitis C and hepatitis B viruses (HBV), poor wound healing |
| Azathioprine (antimetabolite that may cause neutropenia) |
| Possible role in human papillomavirus infection |
| Mycophenolate mofetil (antimetabolite that may cause neutropenia or and/or B cell suppression) |
| Early bacterial infections, possible role in late-onset cytomegalovirus (CMV) |
| Cyclosporine or tacrolimus (calcineurin inhibitors) |
| Increased viral replication, B cell depression, gingival infection, intracellular pathogens |
| Rapamycin (mTor inhibitor) |
| Excess infections in combination with current agents, idiosyncratic pulmonary syndrome, often with concomitant respiratory pathogens, poor wound healing |
| Belatacept (CTLA-4 inhibitor/costimulation blocker) |
| Epstein-Barr virus-mediated post-transplant lymphoproliferative disease, increased CMV severity, PCP |
| Rituximab (anti-CD20 antibody/B cell-depleting antibody) |
| Bacterial and viral infections, particularly reactivation of HBV infection |
| Eculizumab (terminal complement system inhibitor) |
| Encapsulated organisms including pneumococcus, Haemophilus influenzae, and Neisseria meningitidis |
| Plasmapheresis |
| Encapsulated bacteria |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
